Table 2.
Category | Names of CPPs | Experimental Uptake Efficiency | References |
---|---|---|---|
Crot (27–39) and its derivatives | CyLoP-1 | High, higher than D-Tat peptide, penetratin, and D-R8 | [29] |
Crot (27–39) | 78% of CyLoP1 | ||
Crot (27–39) derivative 1 | 63% of CyLoP1 | ||
Crot (27–39) derivative 2 | 66% of CyLoP1 | ||
Crot (27–39) derivative 3 | 61% of CyLoP1 | ||
Crot (27–39) derivative 4 | 59% of CyLoP1 | ||
Crot (27–39) derivative 5 | 47% of CyLoP1 | ||
Crot (27–39) derivative 6 | 42% of CyLoP1 | ||
Crot (27–39) derivative 7 | 75% of CyLoP1 | ||
Crot (27–39) derivative 8 | 39% of CyLoP1 | ||
Crot (27–39) derivative 9 | 26% of CyLoP1 | ||
Crot (27–39) derivative 10 | 79% of CyLoP1 | ||
Crot (27–39) derivative 11 | 58% of CyLoP1 | ||
Crot (27–39) derivative 12 | 29% of CyLoP1 | ||
Crot (27–39) derivative 13 | 83% of CyLoP1 | ||
Crot (27–39) derivative 14 | 37% of CyLoP1 | ||
Crot (27–39) derivative 15 | 46% of CyLoP1 | ||
Penetratin and its derivatives | Penetratin/pAntp (43–58) | Lower than polyarginines but higher than Tat peptide and transportan | [30] |
pAntp (44–58) | 85% of pAntp (43–58) | [31] | |
pAntp (45–58) | 95% of pAntp (43–58) | ||
pAntp (46–58) | 65% of pAntp (43–58) | ||
pAntp (47–58) | 50% of pAntp (43–58) | ||
pAntp (48–58) | 55% of pAntp (43–58) | ||
pAntp (49–58) | 65% of pAntp (43–58) | ||
pAntp (50–58) | 60% of pAntp (43–58) | ||
pAntp (51–58) | 60% of pAntp (43–58) | ||
Ala43 substitution mutant of pAntp (43–58) | 90% of pAntp (43–58) | ||
Ala44 substitution mutant of pAntp (43–58) | 65% of (pAntp) (43–58) | ||
Ala45 substitution mutant of pAntp (43–58) | 80% of pAntp (43–58) | ||
Ala46 substitution mutant of pAntp (43–58) | 50% of pAntp (43–58) | ||
Ala47 substitution mutant of pAntp (43–58) | 55% of pAntp (43–58) | ||
Ala48 substitution mutant of pAntp (43–58) | 65% of pAntp (43–58) | ||
Ala49 substitution mutant of pAntp (43–58) | 90% of pAntp (43–58) | ||
Ala50 substitution mutant of pAntp (43–58) | 90% of pAntp (43–58) | ||
Ala51 substitution mutant of pAntp (43–58) | 60% of pAntp (43–58) | ||
Ala52 substitution mutant of pAntp (43–58) | 45% of pAntp (43–58) | ||
Ala54 substitution mutant of pAntp (43–58) | 90% of pAntp (43–58) | ||
Met-Arg | Not available | [32] | |
pAntpHD (Pro50) | High Comparable to pAntp (43–58) |
[33] | |
CPP derived from PDX-1 protein | PDX-1-PTD | Not available | [34] |
Tumor lineage-homing CPPs | 7 | Not available | [35] |
Peptide 14 and its derivatives | No.14 | Higher than Tat peptide | [36] |
No.14–1 | Higher than Tat and peptide No. 14 | ||
No.14–2 | Higher than Tat peptide | ||
No.14–7 | Higher than Tat and peptide No. 14 | ||
No.14–17 | Equal to Peptide No. 14 | ||
No.14–18 | Higher than Peptide 14 and equal to peptide 14–1 | ||
No.14–20 | Higher than Peptide 14 and equal to peptide 14–1 | ||
No.14–21 | Higher than Peptide 14 and equal to peptide 14–1 | ||
No.14–25 | Equal to peptide 14 | ||
No.14–30 | Higher than peptide 14 and lower than peptide 14–1 | ||
No.14–35 | Higher than Peptide 14 and equal to peptide 14–1 | ||
Cell-penetrating penta peptides
(CPP5s) |
Bip1 | High About 97% of KLPVM |
[37] |
Bip2 | About 61% of KLPVM) | ||
Bip6 | About 71% of KLPVM | ||
Bip15 | Not available | ||
Bip16 | About 70% KLPVM | ||
pVEC (CPP derived from murine vascular endothelial cadherin) | pVEC mutant 1 | Comparable to pVEC | [38] |
pVEC mutant 2 | Higher than pVEC | ||
pVEC mutant 3 | Comparable to pVEC | ||
Tat peptide and its derivatives | Tat (48–60) | High Lower than polyarginine and penetratin but equal to transportan |
[30,39] |
Rev (34–50) | High Comparable to Tat (48–60) |
[40] | |
HIV-1 Rev (34–50) | 2.5-6.6 times more than Tat (48–60) | [41] | |
Retro - Tat (57–49) | High Compared to Tat (49–57) |
[42] | |
Polyarginines | R6 | Lower than R9 | [42] |
R9 | High | ||
Transportan peptide derivative | Transportan 10 (TP10) | High | [43] |
CPPs derived from tumor suppressor protein p14ARF | ARF(1–22) | High Comparable to TP10 |
[43] |
M918 | Higher than Penetratin | [44] | |
α-helical amphipathic CPPs | II | High | [45] |